Breast Cancer
SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor
- Details
ClinicalTrials.gov ID:
NCT04964934
Diagnosis Type:
NA
USOR Number:
- Address
6031 East Woodmen Road, Suite 200
Colorado Springs, CO 80923
P: (719) 577-2555